Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
DarioHealth Corp(DRIO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DRIO
10/09/2026: DRIO (1-star) is currently NOT-A-BUY. Pass it for now.
DarioHealth Corp is a digital health company that provides a multi-condition, AI-driven platform for managing chronic diseases. Its core strength lies in its integrated approach to health services, which helps health plans and employers lower costs through personalized member engagement. The company's primary growth opportunity is the expansion of its platform into high-demand areas like weight management, though it faces significant competitive risks from well-funded incumbents. Financially, the company remains in a growth phase characterized by ongoing operating losses, requiring investors to monitor its path toward cash-flow positivity. This stock may suit risk-tolerant growth investors focused on long-term digital transformation themes within healthcare.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers exposure to high-growth digital health sectors but faces significant execution risks regarding profitability. |
| Momentum investor | Weak fit | The stock has struggled with sustained upward momentum, making it less attractive without a clear breakout signal. |
| Value investor | Weak fit | DarioHealth does not currently meet standard value metrics due to its lack of sustained earnings and cash flow. |
| Dividend investor | Weak fit | The company is a non-dividend-paying growth stock. |
| Low-risk investor | Weak fit | High volatility and operational challenges make this an unsuitable choice for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is prone to sharp swings based on quarterly contract wins or broader sector sentiment. |
| Valuation risk | Medium / high | Valuations are often sentiment-driven given the absence of consistent profitability. |
| Competition risk (Digital Health incumbents) | High | DarioHealth faces intense pressure from better-capitalized incumbents in the digital health space. |
| Business quality | Medium | While the platform is well-regarded, the business model is still proving its path to scale and profitability. |
| Dividend income | Low / none | No income is returned to shareholders. |
| Execution risk | High | Success depends on the complex process of winning and retaining large-scale enterprise contracts. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -65.72% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.84M USD | Price to earnings Ratio - | 1Y Target Price 13.6 |
Price to earnings Ratio - | 1Y Target Price 13.6 | ||
Volume (30-day avg) 23.1K shares | Beta 1.18 | 52 Weeks Range 5.37 - 16.50 | Updated Date 10/09/2026 |
52 Weeks Range 5.37 - 16.50 | Updated Date 10/09/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.28 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Enterprise Services | Platform subscriptions and per-member-per-month fees charged to health plans and employers. | This is the primary revenue engine relying on recurring contracts with large institutional partners. |
| Device and Supplies | Sale of connected glucose meters and necessary testing consumables. | This segment serves as the entry point for users but has shifted to a lower-margin support role for the core platform. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 10.59 | Enterprise Value 84.70M | Price to Sales(TTM) 2.71 |
Enterprise Value 84.70M | Price to Sales(TTM) 2.71 | ||
Enterprise Value to Revenue 4.03 | Enterprise Value to EBITDA -0.59 | Shares Outstanding 9.80M | Shares Floating 6.91M |
Shares Outstanding 9.80M | Shares Floating 6.91M | ||
Percent Insiders 21.65 | Percent Institutions 9.11 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.